|
Pharmaceutical Contract Development and Manufacturing Market Worth $226.35 billion by 2029 - Market Size, Share, Forecasts, & Trends Analysis Report with COVID-19 Impact by Meticulous Research®![]() Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5171 Pharmaceutical contract development and manufacturing organization offers various services based on a contract to small or large pharmaceutical companies. These services include active pharmaceutical ingredient (API) manufacturing, finished dosage form (FDF) manufacturing, drug development & drug discovery services, and biologics manufacturing services. The growth of the pharmaceutical contract development and manufacturing market is attributed to the complex manufacturing requirements of the pharmaceutical industry, manufacturers' growing inclination toward the use of cutting-edge technologies, patent expiration of pharmaceuticals, increasing investments in pharmaceutical R&D, the rising demand for generic medicines & biologics, and the outbreak of the COVID-19 pandemic. In addition, the growing demand for cell and gene therapies and personalized medicines and growth in high potency active pharmaceutical ingredients (HPAPIs) and antibody-drug conjugates (ADCs) markets is expected to offer significant opportunities for the growth of the pharmaceutical contract development and manufacturing market. However, the lack of skilled professionals and the introduction of serialization are some of the challenges to the growth of this market. Impact of COVID-19 on the Pharmaceutical Contract Development and Manufacturing Market The outbreak of the COVID-19 pandemic catalyzed the demand for pharmaceuticals, stirring the development of COVID-19 vaccines, antiviral drugs, antibody therapy, and various other associated pharmaceutical products. According to WHO, the number of COVID-19 cases increased rapidly across the globe. Countries such as the U.S., Most pharmaceutical companies, CDMOs, and research institutes are collaborating to translate research into effective pharmaceutical products and fulfill the abrupt increase in demand. For instance:
Speak to our Analysts to Understand the Impact of COVID-19 on Your Business: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5171 The global pharmaceutical contract development and manufacturing market is segmented on the basis of service {manufacturing [API, FDF (parenteral, tablet, capsule, oral liquid)], drug development, biologics manufacturing, packaging}, end user [large pharma, generic]. The study also evaluates industry competitors and analyzes their market share at global and regional levels. Based on service, the global pharmaceutical contract development and manufacturing market is segmented into pharmaceutical manufacturing services, drug development services, and biologics manufacturing services. In 2022, the pharmaceutical manufacturing services segment is estimated to account for the largest share of the pharmaceutical contract development and manufacturing market. The large market share of this segment is attributed to the growing need to reduce manufacturing costs in the pharmaceutical industry, the increasing requirement for high-quality bulk manufacturing, and the growing demand for generic drugs. However, the biologics manufacturing services segment is expected to grow at the highest CAGR during the forecast period. Based on end user, the pharmaceutical contract development and manufacturing market is segmented into large pharmaceutical companies, small & mid-size pharmaceutical companies, and generic pharmaceutical companies. In 2022, the large pharmaceutical companies segment is estimated to account for the largest share of the pharmaceutical contract development and manufacturing market. However, the generic pharmaceutical companies segment is slated to register the highest growth rate during the forecast period. The high growth of this segment is driven by the increasing competition in the generics market, resulting in pricing pressures and the pharmaceutical industry's inclination toward cutting-edge technologies offered by contract development and manufacturing companies. Quick Buy – Pharmaceutical Contract Development And Manufacturing Market - Global Opportunity Analysis And Industry Forecast (2022-2029): https://www.meticulousresearch.com/Checkout/51512896 Based on geography, in 2022, The report includes an extensive assessment of the service portfolio, geographic analysis, and key strategic developments in the industry's leading market participants over the past four years (2019–2022). The report also covers the list of manufacturing facilities of the major players and market share analysis for the top 19 players in the market. The pharmaceutical contract development and manufacturing market has witnessed several partnerships, collaborations, & agreements; acquisitions; and expansions in recent years. For instance, in Some of the key players operating in this market are Thermo Fisher Scientific Inc. (U.S.), Catalent Inc. (U.S.), Lonza Group Ltd , Recipharm AB , Vetter Pharma International GmbH , Piramal Enterprises Limited , Almac Group (U.K.), Cambrex Corporation (U.S.), Samsung Biologics Co., Ltd , Siegfried Holding AG , FUJIFILM Diosynth Biotechnologies , Aenova Group , Jubilant Pharmova Limited , Curia Global, Inc. (U.S.), C.H. Boehringer Sohn AG & Co. KG , Fareva SA , Fabbrica Italiana Sintetici S.p.A. , WuXi Biologics (Cayman) Inc. , and Aurobindo Pharma Ltd. . Browse in-depth TOC on "Pharmaceutical Contract Development And Manufacturing Market - Global Opportunity Analysis And Industry Forecast (2022-2029)" Scope of the Report: Pharmaceutical Contract Development and Manufacturing Market, by Service
Pharmaceutical Contract Development and Manufacturing Market, by End User
Pharmaceutical Contract Development and Manufacturing Market, by Geography
Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5171 Amidst this crisis, Meticulous Research® is continuously assessing the impact of COVID-19 pandemic on various sub-markets and enables global organizations to strategize for the post-COVID-19 world and sustain their growth. Let us know if you would like to assess the impact of COVID-19 on any industry here- https://www.meticulousresearch.com/custom-research Related Reports: Contract Research Organizations (CRO) Market by Services (Clinical Research [Phase II, Phase III], Pre-Clinical [Pharmacokinetics, Toxicology], Laboratory Services, and others), Therapeutic Area (Oncology, Immunology), End User (Pharma and Biotech, Medical Device), and Geography - Forecast to 2027 https://www.meticulousresearch.com/product/CRO-market-5129/ Pharmaceutical Processing and Packaging Equipment Market by Mode of Delivery (Oral, Parenteral, Topical), Secondary Packaging (Cartoning, Labelling, Serialization), and End-of-Line Packaging (Palletizing, Case Packaging) - Global Forecasts to 2028 https://www.meticulousresearch.com/product/pharmaceutical-processing-and-packaging-equipment-market-5021 About Meticulous Research® Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze, and present the critical market data with great attention to details. With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth. Contact:
SOURCE Meticulous Market Research Pvt. Ltd More Pharmaceuticals News
Search NewsFilter ResultsPublication DateTopic
Provider |
News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.